Considering the improved benefits of NCT03513666A and the IMpower150 trial, a promising treatment was to combine ICIs with chemotherapy to improve the immunogenicity of tumor cells or anti-angiogenesis to promote more TIL infiltration into the tumor in EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.